预约演示
更新于：2025-03-21
Calcium Dobesilate
羟苯磺酸钙
更新于：2025-03-21
概要
基本信息
原研机构- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H12CaO10S2 |
InChIKeyAEWLOKQYGXDGFV-UHFFFAOYSA-N |
CAS号20123-80-2 |
关联
59
项与 羟苯磺酸钙 相关的临床试验NCT06763094
Efficacy of Calcium Dobesilate As an Alternative Method for Treatment of Menorrhagia, Comparison to Tranexamic Acid
CTR20241473
健康受试者空腹及餐后状态下口服羟苯磺酸钙片后
人体生物等效性试验
IRCT20210519051345N38
Fasted-state in vivo bioequivalence study of Calcium Dobesilate 500 mg Capsule manufactured by Abyan Pharmed compared with innovator product
100 项与 羟苯磺酸钙 相关的临床结果
登录后查看更多信息
100 项与 羟苯磺酸钙 相关的转化医学
登录后查看更多信息
100 项与 羟苯磺酸钙 相关的专利（医药）
登录后查看更多信息
585
项与 羟苯磺酸钙 相关的文献（医药）2025-03-01COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
Screening hydrogen bond donors from their surface tension or refractive index to regulate the extraction efficiency of metal ions and organic compounds
作者: Sun, Yulin ; Xu, Chengjin ; Wang, Hongfei
Hydrophobic deep eutectic solvents (HDESs) are considered versatile designer solvents, characterized by a broad range of hydrogen bond acceptors (HBAs) and hydrogen bond donors (HBDs).The selection of appropriate HBDs plays a pivotal role in determining the properties of HDESs.In this work, we propose a model for screening or narrowing the range of suitable HBD reagents to enhance the extraction efficiency of metal ions and organic compoundsThis model utilizes surface tension (γt) or refractive index (nD) as the key parameters for selecting HBDs.The extraction efficiency of metal ions or organic compounds is observed to increase with a decrease in the surface tension or refractive index of the HBDs, as demonstrated in 16 different HDES systems reported in the literature, thereby confirming the reliability of the proposed method.Notably, in contrast to the COSMO-RS model, which necessitates detailed at.-level information about the pure compounds, the surface tension (γt) or refractive index (nD) model (referred to as the SA/RI model) simplifies the process by screening or narrowing the selection of HBDs based solely on these two parameters.Furthermore, by performing linear regression on γt and nD data for 31 HBDs from the literature, we establish the equation γt-(n2D-1)/(2n2D+1), which serves as a reliable tool for assessing the validity of γt and nD values for HBDs.This equation contributes to a deeper understanding of the physicochem. properties of HBDs, facilitating more effective solvent design.
2025-01-06Current molecular medicine
WITHDRAWN: Calcium Dobesilate Attenuates Renal Ischemiareperfusion Injury in a Mouse Model
Article
作者: Cao, Xiao-Jing ; Yang, Le-Le
Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has been
withdrawn the journal Current Molecular Medicine.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The bentham editorial policy on article withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously
submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere
must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting
the article for publication the authors agree that the publishers have the legal right to take appropriate action against the
authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright
of their article is transferred to the publishers if and when the article is accepted for publication.
2024-11-01Biotechnology & genetic engineering reviews
Clinical study on prescription used for invigorating spleen, reinforcing kidney and warming yang combined with calcium dobesilate in treatment of senile diabetic nephropathy
Article
作者: Zhu, Lin ; Zhao, Jianqun ; Li, Qian
OBJECTIVE:
To analyze the clinical effect of prescription used for invigorating spleen, reinforcing kidney and warming yang combined with calcium dobesilate to treat senile diabetic nephropathy (DN).
METHODS:
The clinical data of 110 elderly patients with DN in our hospital from November 2020 to November 2021 were selected for retrospective analysis, and they were divided into the observation group (OG, n = 55) and the control group (CG, n = 55) according to the principle of random grouping. The CG received conventional therapy and calcium dobesilate, and the OG received conventional therapy, calcium dobesilate and prescription used for invigorating spleen, reinforcing kidney and warming yang to evaluate the clinical value of different treatment programs by comparing their clinical indicators after treatment.
RESULTS:
The total effective rate of clinical treatment in the OG was clearly higher than the CG (P < 0.05). The blood glucose indexes, and the levels of ALB and RBP in the OG were visibly lower than the CG after treatment (P < 0.001). After treatment, the average levels of BUN and Cr in the OG were visibly lower than the CG (P < 0.001), while the average eGFR level was significantly higher than the CG (P < 0.001).
CONCLUSION:
The prescription used for invigorating spleen, reinforcing kidney and warming yang combined with calcium dobesilate is a reliable method to improve the hemorheology indexes and renal function of DN patients, which benefits patients, and further studies are helpful to establish a better solution for such patients.
100 项与 羟苯磺酸钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉硬化闭塞症 | 中国 | 1992-07-04 | |
| 慢性静脉功能不全 | 中国 | 1992-07-04 | |
| 高血压 | 中国 | 1992-07-04 | |
| 微血管疾病 | 中国 | 1992-07-04 | |
| 静脉炎 | 中国 | 1992-07-04 | |
| 痉挛 | 中国 | 1992-07-04 | |
| 溃疡 | 中国 | 1992-07-04 | |
| 静脉曲张 | 中国 | 1992-07-04 | |
| 糖尿病性视网膜病变 | 韩国 | 1988-01-19 | |
| 水肿 | 韩国 | 1988-01-19 | |
| 痔疮 | 韩国 | 1988-01-19 | |
| 血栓后综合征 | 韩国 | 1988-01-19 | |
| 静脉功能不全 | 韩国 | 1988-01-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病肾病 | 临床前 | - | 2018-10-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Diabetic) | 糧淵壓糧鹹鏇築餘製壓(鹽遞艱膚築鏇膚遞餘餘) = 醖壓鬱鹽窪繭鹹觸鏇夢 膚壓淵淵襯艱鹹醖膚獵 (選壓顧襯齋遞積鏇淵淵 ) 更多 | - | 2009-04-01 | ||
N/A | 糖尿病性视网膜病变 type 2 diabetes | 194 | Doxium® (DX) 2g | 鹹製餘積簾窪觸獵鹹繭(醖網鑰鹹鬱獵顧廠艱鑰): P-Value = 0.0016 | 积极 | 2004-05-01 | |
Placebo | |||||||
N/A | 194 | 餘壓衊鹹餘鹹簾簾膚選(積艱鑰鑰夢製壓憲夢鏇): P-Value = p0.044 | - | 2004-05-01 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用